EGFR and lung adenocarcinoma: Previous studies have also shown that the co-occurrence of p16/CDKN2A homozygous deletion and activated EGFR mutation in patients with lung adenocarcinoma results in decreased responsiveness to EGFR-TKIs (29, 30).